---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-12T03:28:32.763125'
end_time: '2026-06-12T03:39:45.591427'
duration_seconds: 672.83
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: EDEM2
  gene_symbol: EDEM2
  uniprot_accession: Q9BV94
  protein_description: 'RecName: Full=ER degradation-enhancing alpha-mannosidase-like
    protein 2; Flags: Precursor;'
  gene_info: Name=EDEM2; Synonyms=C20orf31, C20orf49; ORFNames=UNQ573/PRO1135;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the glycosyl hydrolase 47 family. .
  protein_domains: 6hp_glycosidase-like_sf. (IPR012341); EDEM1/2/3. (IPR044674); Glyco_hydro_47.
    (IPR001382); Seven-hairpin_glycosidases. (IPR036026); Glyco_hydro_47 (PF01532)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 20
artifact_count: 2
artifact_sources:
  edison_answer_artifacts: 2
artifacts:
- filename: artifact-00.md
  path: EDEM2-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
- filename: artifact-01.md
  path: EDEM2-deep-research-falcon_artifacts/artifact-01.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-01
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BV94
- **Protein Description:** RecName: Full=ER degradation-enhancing alpha-mannosidase-like protein 2; Flags: Precursor;
- **Gene Information:** Name=EDEM2; Synonyms=C20orf31, C20orf49; ORFNames=UNQ573/PRO1135;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the glycosyl hydrolase 47 family. .
- **Key Domains:** 6hp_glycosidase-like_sf. (IPR012341); EDEM1/2/3. (IPR044674); Glyco_hydro_47. (IPR001382); Seven-hairpin_glycosidases. (IPR036026); Glyco_hydro_47 (PF01532)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EDEM2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EDEM2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EDEM2** (gene ID: EDEM2, UniProt: Q9BV94) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BV94
- **Protein Description:** RecName: Full=ER degradation-enhancing alpha-mannosidase-like protein 2; Flags: Precursor;
- **Gene Information:** Name=EDEM2; Synonyms=C20orf31, C20orf49; ORFNames=UNQ573/PRO1135;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the glycosyl hydrolase 47 family. .
- **Key Domains:** 6hp_glycosidase-like_sf. (IPR012341); EDEM1/2/3. (IPR044674); Glyco_hydro_47. (IPR001382); Seven-hairpin_glycosidases. (IPR036026); Glyco_hydro_47 (PF01532)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EDEM2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EDEM2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EDEM2** (gene ID: EDEM2, UniProt: Q9BV94) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Research Report: Human **EDEM2** (UniProt Q9BV94) Functional Annotation

### 0) Target verification (mandatory)
The retrieved primary and review literature consistently uses **EDEM2** to refer to **endoplasmic reticulum (ER) degradation-enhancing alpha-mannosidase-like protein 2** in **Homo sapiens**, functioning in **N-glycan–dependent ER quality control and ER-associated degradation (ERAD)**, and requiring **TXNDC11** for full function—matching the UniProt Q9BV94 description (george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 2-4).

### 1) Key concepts and definitions (current understanding)

#### 1.1 ER quality control (ERQC) and ER-associated degradation (ERAD)
Secretory-pathway proteins acquire N-linked glycans in the ER and undergo folding with help from lectin chaperones (calnexin/calreticulin). Proteins that fail to fold productively are routed to ERAD, in which they are recognized in the ER lumen, retrotranslocated, ubiquitinated, and degraded by the proteasome (słominskawojewodzka2015theroleof pages 1-4).

#### 1.2 Mannose trimming as a degradation “timer” and signal
A widely cited model is that **progressive demannosylation of oligomannose N-glycans** generates “degradation-competent” glycoforms. Demannosylation can (i) promote exit from calnexin/calreticulin cycling and (ii) generate glycan structures that are recognized by ERAD lectins (e.g., OS9/XTP3B) that deliver substrates to the **SEL1L–HRD1** ERAD machinery (słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7).

#### 1.3 EDEM proteins
**EDEM1/2/3** are **GH47 (class I) α-mannosidase-like** proteins (homologous to the yeast ERAD mannosidase Htm1/Mnl1) that participate in ERAD substrate selection and demannosylation. Reviews emphasize that EDEMs contribute both via **glycan-dependent** recognition/processing and **glycan-independent (chaperone-like)** interactions with misfolded regions (słominskawojewodzka2015theroleof pages 16-19, słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7).

### 2) Core molecular function of EDEM2 (biochemical activity and substrate specificity)

#### 2.1 Reaction catalyzed and glycan branch specificity
A key mechanistic study in human cells established that EDEM2 is required for the **first mannose-trimming step** in mammalian glycoprotein ERAD: **Man9GlcNAc2 (M9) → Man8GlcNAc2 (M8B isomer)** (george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5, george2020edem2stablydisulfidebonded pages 2-4). This is presented as removal of the outermost mannose on the **B-branch**, producing **M8B** as the product glycoform that enters subsequent trimming steps (george2020edem2stablydisulfidebonded pages 2-4).

#### 2.2 Preference for misfolded/unfolded glycoprotein substrates
In vitro work measuring EDEM activities reported that EDEM2 has **modest** mannosidase activity on free glycans and native glycoproteins, but **substantially higher activity on denatured/unfolded glycoproteins**, consistent with preferential action on ERAD clients rather than properly folded secretory proteins (shenkman2018mannosidaseactivityof pages 4-5, shenkman2018mannosidaseactivityof pages 4-4).

#### 2.3 Requirement for oxidoreductase partners to enable activity
A central resolution to earlier “no activity” results is that EDEM2 requires an ER oxidoreductase partner. In human HCT116 cells, EDEM2 forms a **stable disulfide-bonded complex with TXNDC11**, and this covalent partnership is essential for mannose trimming and downstream ERAD (george2020edem2stablydisulfidebonded pages 9-10, george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5).

### 3) Localization and topology (where EDEM2 acts)
EDEM2 is described as an **ER-resident** factor functioning in the ER lumenal quality-control environment, where it participates in the earliest demannosylation step that commits glycoproteins to ERAD (murase2023regulationofthe pages 1-2, george2020edem2stablydisulfidebonded pages 2-4). Consistent with its role, reviews place EDEM proteins upstream of lectin-mediated delivery to SEL1L–HRD1 and downstream retrotranslocation (słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7).

### 4) Pathway placement and interacting partners

#### 4.1 TXNDC11 is a required functional partner (disulfide-linked complex)
George et al. showed EDEM2 is **stably disulfide-bonded** to TXNDC11, specifically **EDEM2 Cys558** linked to **TXNDC11 Cys692** (in TXNDC11’s Trx5 domain). Disrupting this bond (EDEM2 C558A or TXNDC11 C692S) prevents mannose trimming and impairs ERAD in cells (george2020edem2stablydisulfidebonded pages 9-10, george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5). The purified **EDEM2–TXNDC11** complex displayed in vitro activity converting M9 to M8B, directly supporting enzymatic function of the complex (george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5).

#### 4.2 Association with PDI-family oxidoreductases
EDEM2 was also reported to associate with **PDI**, and oxidoreductases (including TXNDC11 and PDI) enhanced EDEM2 activity in vitro in the unfolded-substrate assays (shenkman2018mannosidaseactivityof pages 4-5, george2020edem2stablydisulfidebonded pages 4-5, shenkman2018mannosidaseactivityof pages 4-4). Reviews place mammalian EDEM proteins within a broader paradigm of **mannosidase–PDI-like complexes** in ERAD initiation (suzuki2021foldingandquality pages 11-12).

#### 4.3 Downstream lectins and ERAD machinery (OS9/XTP3B; SEL1L–HRD1)
Expert reviews describe that mannose trimming by EDEMs ultimately generates glycans exposing an **α1,6-linked mannose** recognized by **MRH-domain lectins OS9 and XTP3B**, which target substrates to the **SEL1L–HRD1** dislocation/ubiquitination complex (słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7). In updated pathway framing, EDEM2 provides the initiating M9→M8B step before further trimming by EDEM3/EDEM1, leading to OS9/XTP3B recruitment and delivery to SEL1L–HRD1 (ninagawa2024uggt1mediatedreglucosylationof pages 5-9).

### 5) Recent developments (prioritizing 2023–2024)

#### 5.1 2023: Endogenous regulation of EDEM2 in HEK293 cells
Murase et al. (Jan 2023; BPB Reports; https://doi.org/10.1248/bpbreports.6.6_193) reported that ER stress increased EDEM2 mRNA in HEK293 cells, consistent with linkage to the **IRE1–sXBP1** arm of the UPR, but EDEM2 protein abundance was strongly shaped by post-transcriptional mechanisms (murase2023regulationofthe pages 1-2). TXNDC11 deficiency decreased EDEM2 protein, consistent with TXNDC11 supporting EDEM2 stability/function (murase2023regulationofthe pages 1-2). They also provide evidence that EDEM2 itself is at least partly subject to **SEL1L-mediated ERAD**, since DTT-driven loss of EDEM2 was partly rescued by MG132 or SEL1L deficiency (murase2023regulationofthe pages 1-2).

#### 5.2 2024: “Tug-of-war” model—UGGT1 reglucosylation competes with EDEM-driven ERAD commitment
Ninagawa et al. (Sep 2024; eLife; https://doi.org/10.1101/2023.10.18.562958) provides a modern model of ERQC decision-making: **UGGT1-mediated reglucosylation** supports continued calnexin/calreticulin folding cycles, while **EDEM-mediated mannose trimming** commits substrates to gpERAD (ninagawa2024uggt1mediatedreglucosylationof pages 5-9, ninagawa2024uggt1mediatedreglucosylationof pages 1-5). Their gene-disruption experiments show that UGGT1 loss accelerates degradation of unstable/misfolded glycoproteins (e.g., ATF6α, NHK), and that this accelerated degradation depends on the mannose-trimming ERAD route (blocked in SEL1L-KO and EDEM-family knockout backgrounds, and stabilized by the mannosidase inhibitor **kifunensine**) (ninagawa2024uggt1mediatedreglucosylationof pages 5-9, ninagawa2024uggt1mediatedreglucosylationof pages 9-12).

### 6) Current applications and real-world implementations

#### 6.1 Chemical and experimental modulation of the EDEM2 pathway
Class I α-mannosidase inhibitors are used to experimentally suppress mannose trimming and thereby alter ERAD commitment. In the 2024 pathway study, kifunensine stabilized an ERAD substrate (ATF6α) under conditions that otherwise accelerate degradation, supporting its use as a functional probe of the EDEM-dependent mannose trimming route (ninagawa2024uggt1mediatedreglucosylationof pages 5-9).

#### 6.2 Translational/clinical-bioinformatics applications: EDEM2 as a biomarker candidate
Wu et al. (Jan 2023; Frontiers in Oncology; https://doi.org/10.3389/fonc.2022.1054012) reported EDEM2 overexpression in glioma datasets and validated expression by qPCR/IHC; EDEM2 knockdown reduced glioma cell migration/invasion in vitro (wu2023edem2isa pages 9-11). They also reported biomarker-like statistics: a prognostic nomogram including EDEM2 had **C-index = 0.847**, and EDEM2 expression predicted immunotherapy response with ROC **AUC = 0.857** and **0.839** in two datasets; additional ROC AUCs included **0.988** for pathological grade and **0.673** for IDH status (wu2023edem2isa pages 9-11). EDEM2 expression correlated with tumor mutation burden (**r = 0.473**, **p < 0.001**) (wu2023edem2isa pages 9-11).

### 7) Expert synthesis: consensus, competing models, and open questions

#### 7.1 Consensus model for EDEM2’s role
Across primary and review sources, the convergent model is: EDEM2 (with TXNDC11) performs the **initial** demannosylation step (M9→M8B), which enables subsequent EDEM-mediated processing and creation of glycan signals recognized by OS9/XTP3B for delivery to SEL1L–HRD1 ERAD (george2020edem2stablydisulfidebonded pages 1-2, ninagawa2024uggt1mediatedreglucosylationof pages 5-9, suzuki2021foldingandquality pages 11-12, słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7).

#### 7.2 Open mechanistic questions
Reviews emphasize that EDEMs can contribute via both **enzymatic trimming** and **chaperone-like substrate binding** (including glycan-independent binding to hydrophobic regions), and discuss alternative models in which EDEMs primarily (i) trigger demannosylation based on hydrophobic exposure, (ii) recognize misfolded proteins independently of trimming, or (iii) serve as delivery factors to the retrotranslocon (słominskawojewodzka2015theroleof pages 16-19, słominskawojewodzka2015theroleof pages 10-12). Recent regulation work also highlights incomplete understanding of how ER redox conditions and reducing agents affect the stability and association of EDEM2–TXNDC11 and unbound EDEM2 in vivo (murase2023regulationofthe pages 7-7).

### 8) Summary tables (evidence at a glance)

| Source | Year | Journal | Experimental system / assays | Enzymatic reaction | Substrate specificity / preferences | Required binding partners | Main mechanistic conclusion | URL | Evidence |
|---|---:|---|---|---|---|---|---|---|---|
| George et al. | 2020 | *eLife* | Human HCT116 cells; EDEM2 knockout/rescue; cycloheximide chase; co-immunoprecipitation; non-reducing SDS-PAGE; purified complex in vitro glycan-trimming assays | Converts **Man9GlcNAc2 (M9)** to **Man8GlcNAc2 isomer B (M8B)**, the first demannosylation step in mammalian glycoprotein ERAD | B-branch-specific removal of the outermost α1,2-linked mannose from M9; acts on ERAD glycoprotein substrates | **TXNDC11 required** via stable intermolecular disulfide bond (**EDEM2 C558–TXNDC11 C692**); **PDI associates** with EDEM2 but TXNDC11 is essential for full activity | Established human EDEM2 as the **initiator mannosidase** of gpERAD; EDEM2 alone is insufficient, but the **EDEM2–TXNDC11 complex** is catalytically active in vitro and required in cells for substrate trimming and degradation | https://doi.org/10.7554/elife.53455 | (george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5, george2020edem2stablydisulfidebonded pages 2-4) |
| Shenkman et al. | 2018 | *Communications Biology* | Human cell-derived immunoprecipitated EDEM2; in vitro glycan trimming; HPLC analysis of free glycans, native glycoproteins, and denatured glycoproteins; co-IP | Demonstrated bona fide α-mannosidase activity of EDEM2 on glycoprotein N-glycans; trimming observed from higher-mannose forms toward **M7–M5** in vitro | Activity is modest on free oligosaccharides and native glycoproteins but **markedly enhanced on denatured/unfolded glycoproteins**; supports preference for misfolded ERAD clients | **TXNDC11 and PDI interact** with EDEM2; oxidoreductases enhance activity on glycoproteins | EDEM2 is a functional ERAD mannosidase whose activity is **folding-state sensitive**, providing a mechanism for preferential targeting of unfolded/misfolded glycoproteins | https://doi.org/10.1038/s42003-018-0174-8 | (shenkman2018mannosidaseactivityof pages 4-5, shenkman2018mannosidaseactivityof pages 4-4) |
| Murase et al. | 2023 | *BPB Reports* | HEK293 cells; ER stress induction (thapsigargin, tunicamycin, brefeldin A); MG132, DTT, cycloheximide; SEL1L- and TXNDC11-deficient cells; immunoblotting/qPCR | Supports EDEM2 as the **earliest ER-resident ERAD mannosidase** in the pathway rather than redefining the catalytic chemistry | Substrates are misfolded **N-glycosylated ER proteins** entering SEL1L-HRD1-dependent ERAD | **TXNDC11 stabilizes EDEM2** and supports its activity; EDEM2 also physically/functionally links to **SEL1L-mediated ERAD** | Recent evidence indicates EDEM2 is **post-transcriptionally regulated**, depends on TXNDC11 for protein stability, and is itself at least partly turned over by **SEL1L-mediated ERAD** | https://doi.org/10.1248/bpbreports.6.6_193 | (murase2023regulationofthe pages 1-2, murase2023regulationofthe pages 2-4) |
| Ninagawa et al. | 2024 | *eLife* | Gene-disrupted cells for UGGT1/2, SEL1L, and EDEM family components; degradation assays of ATF6α, NHK, and other ERAD substrates; inhibitor studies (kifunensine, DNJ) | Places EDEM2 at the first mannose-trimming step (**M9→M8B**) within the broader sequential ERAD pathway that competes with UGGT1-mediated reglucosylation | EDEM-dependent pathway acts on **unstable/misfolded glycoproteins** destined for OS9/XTP3B recognition and HRD1-SEL1L delivery | EDEM2 functions as part of the **EDEM2–TXNDC11** initiating step; downstream EDEM1/3 perform further trimming | Current pathway model: glycoprotein fate is a **tug-of-war between UGGT1-mediated refolding cycles and EDEM-driven mannose trimming**; EDEM2 is the entry-point enzyme for degradation-directed trimming | https://doi.org/10.1101/2023.10.18.562958 | (ninagawa2024uggt1mediatedreglucosylationof pages 5-9, ninagawa2024uggt1mediatedreglucosylationof pages 12-16, ninagawa2024uggt1mediatedreglucosylationof pages 9-12, ninagawa2024uggt1mediatedreglucosylationof pages 1-5) |


*Table: This table summarizes primary mechanistic evidence for human EDEM2, including its catalytic reaction, substrate preferences, dependence on TXNDC11 and association with PDI, and the experimental systems used to define its role in glycoprotein ERAD. It is useful for functional annotation because it distinguishes direct biochemical evidence from broader pathway and regulatory studies.*

| Paper | Publication date | Topic | Key findings | Key quantitative results | URL | Citation |
|---|---|---|---|---|---|---|
| Murase et al., *Regulation of the ER-Resident Mannosidase EDEM2 in HEK293 Cells* | Jan 2023 | Regulation | EDEM2 is an ER-resident initiator mannosidase whose expression is modestly induced by ER stress but regulated strongly post-transcriptionally; TXNDC11 supports EDEM2 stability, and EDEM2 is at least partly turned over by SEL1L-mediated ERAD | EDEM2 mRNA decreased ~30% after 6 h MG132/CMA/CHX; EDEM2 protein decreased ~50% after 24 h CHX; TXNDC11 deficiency reduced EDEM2 protein; DTT-induced loss was partly rescued by MG132 or SEL1L deficiency | https://doi.org/10.1248/bpbreports.6.6_193 | (murase2023regulationofthe pages 2-4, murase2023regulationofthe pages 1-2) |
| Wu et al., *EDEM2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: A comprehensive analysis* | Jan 2023 | Disease biomarker | EDEM2 is overexpressed in glioma, associated with poor prognosis, immune infiltration, and greater invasiveness; knockdown reduced U251 migration/invasion; high EDEM2 associated with ICI response and higher TMB | Nomogram C-index = 0.847; ICI-response AUCs = 0.857 and 0.839; diagnostic AUC = 0.988 for pathological grade and 0.673 for IDH status; TMB correlation r = 0.473, p < 0.001; mutation frequency 0.4% in LGG and 0.7% in GBM | https://doi.org/10.3389/fonc.2022.1054012 | (wu2023edem2isa pages 1-2, wu2023edem2isa pages 9-11) |
| Ninagawa et al., *UGGT1-mediated reglucosylation of N-glycan competes with ER-associated degradation of unstable and misfolded glycoproteins* | Sep 2024 | Mechanism / pathway update | Updated ERQC model in which UGGT1-driven reglucosylation competes with EDEM-mediated mannose trimming; EDEM2 is the initiating M9→M8B step, upstream of EDEM3/EDEM1 and OS9/XTP3B delivery to SEL1L-HRD1 | UGGT1-KO and UGGT-DKO accelerated degradation of ATF6α and NHK; UGGT2-KO had little effect; degradation was blocked in SEL1L-KO and EDEM-TKO cells; kifunensine stabilized ATF6α in UGGT-DKO; no EDEM2-specific numeric AUC/correlation metrics reported | https://doi.org/10.1101/2023.10.18.562958 | (ninagawa2024uggt1mediatedreglucosylationof pages 5-9, ninagawa2024uggt1mediatedreglucosylationof pages 12-16, ninagawa2024uggt1mediatedreglucosylationof pages 9-12, ninagawa2024uggt1mediatedreglucosylationof pages 1-5) |


*Table: This table lists the 2023-2024 EDEM2-related papers identified in the current evidence set, organized by topic and publication date. It highlights the most useful quantitative results and pathway-level takeaways for mechanism, regulation, and biomarker interpretation.*

### 9) Key takeaways for functional annotation
- **Primary molecular function:** EDEM2 is an ER-resident GH47 α-mannosidase-like enzyme that, when complexed with **TXNDC11**, catalyzes the **first** N-glycan mannose trimming step in gpERAD: **Man9GlcNAc2 → Man8GlcNAc2 (isomer B)** (george2020edem2stablydisulfidebonded pages 1-2, george2020edem2stablydisulfidebonded pages 4-5).
- **Substrate preference:** EDEM2 activity is higher on **unfolded/denatured glycoprotein substrates**, consistent with preferential processing of misfolded ER clients (shenkman2018mannosidaseactivityof pages 4-5, shenkman2018mannosidaseactivityof pages 4-4).
- **Cellular compartment:** ER (ERQC/ERAD pathway) (murase2023regulationofthe pages 1-2, george2020edem2stablydisulfidebonded pages 2-4).
- **Core partners:** TXNDC11 (obligate disulfide-linked partner for activity), and association with PDI-family oxidoreductases (george2020edem2stablydisulfidebonded pages 9-10, shenkman2018mannosidaseactivityof pages 4-5, george2020edem2stablydisulfidebonded pages 4-5).
- **Pathway context:** Mannose trimming by EDEM2/EDEMs enables recognition by OS9/XTP3B and delivery to SEL1L–HRD1, balanced against UGGT1-driven reglucosylation that favors folding (ninagawa2024uggt1mediatedreglucosylationof pages 5-9, słominskawojewodzka2015theroleof pages 10-12, adams2019proteinqualitycontrol pages 6-7).



References

1. (george2020edem2stablydisulfidebonded pages 1-2): Ginto George, Satoshi Ninagawa, Hirokazu Yagi, Taiki Saito, Tokiro Ishikawa, Tetsushi Sakuma, Takashi Yamamoto, Koshi Imami, Yasushi Ishihama, Koichi Kato, Tetsuya Okada, and Kazutoshi Mori. Edem2 stably disulfide-bonded to txndc11 catalyzes the first mannose trimming step in mammalian glycoprotein erad. eLife, Feb 2020. URL: https://doi.org/10.7554/elife.53455, doi:10.7554/elife.53455. This article has 58 citations and is from a domain leading peer-reviewed journal.

2. (george2020edem2stablydisulfidebonded pages 2-4): Ginto George, Satoshi Ninagawa, Hirokazu Yagi, Taiki Saito, Tokiro Ishikawa, Tetsushi Sakuma, Takashi Yamamoto, Koshi Imami, Yasushi Ishihama, Koichi Kato, Tetsuya Okada, and Kazutoshi Mori. Edem2 stably disulfide-bonded to txndc11 catalyzes the first mannose trimming step in mammalian glycoprotein erad. eLife, Feb 2020. URL: https://doi.org/10.7554/elife.53455, doi:10.7554/elife.53455. This article has 58 citations and is from a domain leading peer-reviewed journal.

3. (słominskawojewodzka2015theroleof pages 1-4): Monika Słomińska-Wojewódzka and Kirsten Sandvig. The role of lectin-carbohydrate interactions in the regulation of er-associated protein degradation. Molecules, 20:9816-9846, May 2015. URL: https://doi.org/10.3390/molecules20069816, doi:10.3390/molecules20069816. This article has 63 citations.

4. (słominskawojewodzka2015theroleof pages 10-12): Monika Słomińska-Wojewódzka and Kirsten Sandvig. The role of lectin-carbohydrate interactions in the regulation of er-associated protein degradation. Molecules, 20:9816-9846, May 2015. URL: https://doi.org/10.3390/molecules20069816, doi:10.3390/molecules20069816. This article has 63 citations.

5. (adams2019proteinqualitycontrol pages 6-7): Benjamin M. Adams, Michela E. Oster, and Daniel N. Hebert. Protein quality control in the endoplasmic reticulum. The Protein Journal, 38:317-329, Apr 2019. URL: https://doi.org/10.1007/s10930-019-09831-w, doi:10.1007/s10930-019-09831-w. This article has 147 citations.

6. (słominskawojewodzka2015theroleof pages 16-19): Monika Słomińska-Wojewódzka and Kirsten Sandvig. The role of lectin-carbohydrate interactions in the regulation of er-associated protein degradation. Molecules, 20:9816-9846, May 2015. URL: https://doi.org/10.3390/molecules20069816, doi:10.3390/molecules20069816. This article has 63 citations.

7. (george2020edem2stablydisulfidebonded pages 4-5): Ginto George, Satoshi Ninagawa, Hirokazu Yagi, Taiki Saito, Tokiro Ishikawa, Tetsushi Sakuma, Takashi Yamamoto, Koshi Imami, Yasushi Ishihama, Koichi Kato, Tetsuya Okada, and Kazutoshi Mori. Edem2 stably disulfide-bonded to txndc11 catalyzes the first mannose trimming step in mammalian glycoprotein erad. eLife, Feb 2020. URL: https://doi.org/10.7554/elife.53455, doi:10.7554/elife.53455. This article has 58 citations and is from a domain leading peer-reviewed journal.

8. (shenkman2018mannosidaseactivityof pages 4-5): Marina Shenkman, Efrat Ron, Rivka Yehuda, Ron Benyair, Isam Khalaila, and Gerardo Z. Lederkremer. Mannosidase activity of edem1 and edem2 depends on an unfolded state of their glycoprotein substrates. Communications Biology, Oct 2018. URL: https://doi.org/10.1038/s42003-018-0174-8, doi:10.1038/s42003-018-0174-8. This article has 71 citations and is from a peer-reviewed journal.

9. (shenkman2018mannosidaseactivityof pages 4-4): Marina Shenkman, Efrat Ron, Rivka Yehuda, Ron Benyair, Isam Khalaila, and Gerardo Z. Lederkremer. Mannosidase activity of edem1 and edem2 depends on an unfolded state of their glycoprotein substrates. Communications Biology, Oct 2018. URL: https://doi.org/10.1038/s42003-018-0174-8, doi:10.1038/s42003-018-0174-8. This article has 71 citations and is from a peer-reviewed journal.

10. (george2020edem2stablydisulfidebonded pages 9-10): Ginto George, Satoshi Ninagawa, Hirokazu Yagi, Taiki Saito, Tokiro Ishikawa, Tetsushi Sakuma, Takashi Yamamoto, Koshi Imami, Yasushi Ishihama, Koichi Kato, Tetsuya Okada, and Kazutoshi Mori. Edem2 stably disulfide-bonded to txndc11 catalyzes the first mannose trimming step in mammalian glycoprotein erad. eLife, Feb 2020. URL: https://doi.org/10.7554/elife.53455, doi:10.7554/elife.53455. This article has 58 citations and is from a domain leading peer-reviewed journal.

11. (murase2023regulationofthe pages 1-2): Ryoichi Murase, Genki Kato, and Kentaro Oh-hashi. Regulation of the er-resident mannosidase edem2 in hek293 cells. BPB Reports, 6:193-199, Jan 2023. URL: https://doi.org/10.1248/bpbreports.6.6\_193, doi:10.1248/bpbreports.6.6\_193. This article has 3 citations.

12. (suzuki2021foldingandquality pages 11-12): Tadashi Suzuki and Haruhiko Fujihira. Folding and quality control of glycoproteins. Comprehensive Glycoscience, pages 1-28, Dec 2021. URL: https://doi.org/10.1016/b978-0-12-409547-2.14947-9, doi:10.1016/b978-0-12-409547-2.14947-9. This article has 12 citations.

13. (ninagawa2024uggt1mediatedreglucosylationof pages 5-9): Satoshi Ninagawa, Masaki Matsuo, Deng Ying, Shuichiro Oshita, Shinya Aso, Kazutoshi Matsushita, Mai Taniguchi, Akane Fueki, Moe Yamashiro, Kaoru Sugasawa, Shunsuke Saito, Koshi Imami, Yasuhiko Kizuka, Tetsushi Sakuma, Takashi Yamamoto, Hirokazu Yagi, Koichi Kato, and Kazutoshi Mori. Uggt1-mediated reglucosylation of n-glycan competes with er-associated degradation of unstable and misfolded glycoproteins. eLife, Sep 2024. URL: https://doi.org/10.1101/2023.10.18.562958, doi:10.1101/2023.10.18.562958. This article has 7 citations and is from a domain leading peer-reviewed journal.

14. (ninagawa2024uggt1mediatedreglucosylationof pages 1-5): Satoshi Ninagawa, Masaki Matsuo, Deng Ying, Shuichiro Oshita, Shinya Aso, Kazutoshi Matsushita, Mai Taniguchi, Akane Fueki, Moe Yamashiro, Kaoru Sugasawa, Shunsuke Saito, Koshi Imami, Yasuhiko Kizuka, Tetsushi Sakuma, Takashi Yamamoto, Hirokazu Yagi, Koichi Kato, and Kazutoshi Mori. Uggt1-mediated reglucosylation of n-glycan competes with er-associated degradation of unstable and misfolded glycoproteins. eLife, Sep 2024. URL: https://doi.org/10.1101/2023.10.18.562958, doi:10.1101/2023.10.18.562958. This article has 7 citations and is from a domain leading peer-reviewed journal.

15. (ninagawa2024uggt1mediatedreglucosylationof pages 9-12): Satoshi Ninagawa, Masaki Matsuo, Deng Ying, Shuichiro Oshita, Shinya Aso, Kazutoshi Matsushita, Mai Taniguchi, Akane Fueki, Moe Yamashiro, Kaoru Sugasawa, Shunsuke Saito, Koshi Imami, Yasuhiko Kizuka, Tetsushi Sakuma, Takashi Yamamoto, Hirokazu Yagi, Koichi Kato, and Kazutoshi Mori. Uggt1-mediated reglucosylation of n-glycan competes with er-associated degradation of unstable and misfolded glycoproteins. eLife, Sep 2024. URL: https://doi.org/10.1101/2023.10.18.562958, doi:10.1101/2023.10.18.562958. This article has 7 citations and is from a domain leading peer-reviewed journal.

16. (wu2023edem2isa pages 9-11): Yuxi Wu, Haofei Wang, Wei Xiang, and Dongye Yi. Edem2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: a comprehensive analysis. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1054012, doi:10.3389/fonc.2022.1054012. This article has 8 citations.

17. (murase2023regulationofthe pages 7-7): Ryoichi Murase, Genki Kato, and Kentaro Oh-hashi. Regulation of the er-resident mannosidase edem2 in hek293 cells. BPB Reports, 6:193-199, Jan 2023. URL: https://doi.org/10.1248/bpbreports.6.6\_193, doi:10.1248/bpbreports.6.6\_193. This article has 3 citations.

18. (murase2023regulationofthe pages 2-4): Ryoichi Murase, Genki Kato, and Kentaro Oh-hashi. Regulation of the er-resident mannosidase edem2 in hek293 cells. BPB Reports, 6:193-199, Jan 2023. URL: https://doi.org/10.1248/bpbreports.6.6\_193, doi:10.1248/bpbreports.6.6\_193. This article has 3 citations.

19. (ninagawa2024uggt1mediatedreglucosylationof pages 12-16): Satoshi Ninagawa, Masaki Matsuo, Deng Ying, Shuichiro Oshita, Shinya Aso, Kazutoshi Matsushita, Mai Taniguchi, Akane Fueki, Moe Yamashiro, Kaoru Sugasawa, Shunsuke Saito, Koshi Imami, Yasuhiko Kizuka, Tetsushi Sakuma, Takashi Yamamoto, Hirokazu Yagi, Koichi Kato, and Kazutoshi Mori. Uggt1-mediated reglucosylation of n-glycan competes with er-associated degradation of unstable and misfolded glycoproteins. eLife, Sep 2024. URL: https://doi.org/10.1101/2023.10.18.562958, doi:10.1101/2023.10.18.562958. This article has 7 citations and is from a domain leading peer-reviewed journal.

20. (wu2023edem2isa pages 1-2): Yuxi Wu, Haofei Wang, Wei Xiang, and Dongye Yi. Edem2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: a comprehensive analysis. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1054012, doi:10.3389/fonc.2022.1054012. This article has 8 citations.

## Artifacts

- [Edison artifact artifact-00](EDEM2-deep-research-falcon_artifacts/artifact-00.md)
- [Edison artifact artifact-01](EDEM2-deep-research-falcon_artifacts/artifact-01.md)

## Citations

1. suzuki2021foldingandquality pages 11-12
2. murase2023regulationofthe pages 1-2
3. murase2023regulationofthe pages 7-7
4. adams2019proteinqualitycontrol pages 6-7
5. shenkman2018mannosidaseactivityof pages 4-5
6. shenkman2018mannosidaseactivityof pages 4-4
7. murase2023regulationofthe pages 2-4
8. https://doi.org/10.1248/bpbreports.6.6_193
9. https://doi.org/10.1101/2023.10.18.562958
10. https://doi.org/10.3389/fonc.2022.1054012
11. https://doi.org/10.7554/elife.53455
12. https://doi.org/10.1038/s42003-018-0174-8
13. https://doi.org/10.7554/elife.53455,
14. https://doi.org/10.3390/molecules20069816,
15. https://doi.org/10.1007/s10930-019-09831-w,
16. https://doi.org/10.1038/s42003-018-0174-8,
17. https://doi.org/10.1248/bpbreports.6.6\_193,
18. https://doi.org/10.1016/b978-0-12-409547-2.14947-9,
19. https://doi.org/10.1101/2023.10.18.562958,
20. https://doi.org/10.3389/fonc.2022.1054012,